CClinicalTrials.gg
RecruitingNCT06033040Updated Sep 13, 2023

Medical Imaging in Bladder Tumors by MRI

An observational study in Bladder Tumor and Magnetic Resonance Imaging, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 1 month later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
178
Sex
All
01

Study summary

This study prospectively included 178 patients with bladder neoplastic lesions who planned to undergo surgery (with or without preoperative neoadjuvant chemotherapy). Inclusion criteria: Patients with pathologically confirmed bladder cancer after radical or partial cystectomy or TURBT (\< 2 weeks between surgical resection and imaging). Exclusion criteria: 1) Prior history of chemotherapy and/or radiotherapy; 2) No surgical resection; 3) The interval between surgical resection and imaging examination is > 2 weeks; 4) Obvious artifacts; 5)MRI scan contraindications. All subjects underwent pelvic MRI. Data was collected using a Siemens VIDA 3TMR scanner (Siemens Healthcare, Erlangen, Germany). All subjects underwent standardized scanning protocols. The obtained images are post-processed and the experimental results are analyzed statistically.

02

Conditions studied

  • Bladder Tumor
  • Magnetic Resonance Imaging
03

In context

Urinary Bladder Neoplasms

1,616 studies on the registry are indexed under Urinary Bladder Neoplasms; 421 are open to participants now.

This study's planned enrollment of 178 is close to the median of 180 across 374 observational studies indexed under Urinary Bladder Neoplasms.

Browse Urinary Bladder Neoplasms studies →

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 466 studies on the registry; 271 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with bladder neoplasm planned to undergo surgery

Inclusion criteria

  1. Clinical diagnosis of bladder neoplasm
  2. Must undergo radical or partial cystectomy or TURBT surgery within 2 weeks between surgical resection and imaging

Exclusion criteria

Exclusion Criteria:

  1. A history of pelvic radiotherapy or chemotherapy;
  2. Lack of pathological findings or no surgery;
  3. The interval between surgical resection and imaging examination > 2 weeks;
  4. Poor image quality due to poor coordination or motion artifacts;
  5. MRI scan contraindications
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
178 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes

Interventions

  • OtherMRI

    Functional sequence imaging (MDME, IVIM) sequences were added to the routine MRI scan of patients with bladder tumor

06

What researchers measure

Primary outcomes

  1. quantitative parameters by MRI

    quantitative parameters by functional MRI

    Time frame: From the time the participants completed the MRI scan to the post-processing of the resulting images,assessed up to 2 months

07

Study locations

1 of 1 sites recruiting
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guang Dong 510000, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06033040
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Aug 15, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Sep 13, 2023

Study contacts

Yuan Luo, master
Contact
luoy289@mail2.sysu.edu.cn
8618816791193

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion